Immune self-reactivity triggered by drug-modified HLA-peptide repertoire
Illing, Patricia T., Vivian, Julian P., Dudek, Nadine L., Kostenko, Lyudmila, Chen, Zhenjun, Bharadwaj, Mandvi, Miles, John J., Kjer-Nielsen, Lars, Gras, Stephanie, Williamson, Nicholas A., Burrows, Scott R., Purcell, Anthony W., Rossjohn, Jamie, and McCluskey, James (2012) Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature, 486 (7404). pp. 554-558.
PDF (Published Version)
- Published Version
Restricted to Repository staff only |
Abstract
Human leukocyte antigens (HLAs) are highly polymorphic proteins that initiate immunity by presenting pathogen-derived peptides to T cells. HLA polymorphisms mostly map to the antigen-binding cleft, thereby diversifying the repertoire of self-derived and pathogen-derived peptide antigens selected by different HLA allotypes. A growing number of immunologically based drug reactions, including abacavir hypersensitivity syndrome (AHS) and carbamazepine-induced Stevens–Johnson syndrome (SJS), are associated with specific HLA alleles. However, little is known about the underlying mechanisms of these associations, including AHS, a prototypical HLA-associated drug reaction occurring exclusively in individuals with the common histocompatibility allele HLA-B*57:01, and with a relative risk of more than 1,000. We show that unmodified abacavir binds non-covalently to HLA-B*57:01, lying across the bottom of the antigen-binding cleft and reaching into the F-pocket, where a carboxy-terminal tryptophan typically anchors peptides bound to HLA-B*57:01. Abacavir binds with exquisite specificity to HLA-B*57:01, changing the shape and chemistry of the antigen-binding cleft, thereby altering the repertoire of endogenous peptides that can bind HLA-B*57:01. In this way, abacavir guides the selection of new endogenous peptides, inducing a marked alteration in 'immunological self'. The resultant peptide-centric 'altered self' activates abacavir-specific T-cells, thereby driving polyclonal CD8 T-cell activation and a systemic reaction manifesting as AHS. We also show that carbamazepine, a widely used anti-epileptic drug associated with hypersensitivity reactions in HLA-B*15:02 individuals, binds to this allotype, producing alterations in the repertoire of presented self peptides. Our findings simultaneously highlight the importance of HLA polymorphism in the evolution of pharmacogenomics and provide a general mechanism for some of the growing number of HLA-linked hypersensitivities that involve small-molecule drugs.
Item ID: | 45189 |
---|---|
Item Type: | Article (Research - C1) |
ISSN: | 1476-4687 |
Funders: | National Health and Medical Research Council of Australia (NHMRC), Australian Research Council (ARC), Monash University (MU) |
Date Deposited: | 23 Aug 2016 04:47 |
FoR Codes: | 11 MEDICAL AND HEALTH SCIENCES > 1107 Immunology > 110702 Applied Immunology (incl Antibody Engineering, Xenotransplantation and T-cell Therapies) @ 100% |
SEO Codes: | 92 HEALTH > 9201 Clinical Health (Organs, Diseases and Abnormal Conditions) > 920108 Immune System and Allergy @ 100% |
Downloads: |
Total: 3 |
More Statistics |